-
-
-
-
-
-
-
Chimerix (CMRX) Appoints Marc D. Kozin to its Board
-
-
-
-
-
-
-
Chimerix (CMRX) and Emergent BioSolutions (EBS) Disclose Expiration of HSR Waiting Period for Acquisition of Rights to Brincidofovir
-
-
-
-
-
-
-
Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
-
-
-
-
-
-
-
Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting
-
-
-
-
-
-
-
Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021
-
-
-
-
-
-
-
Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
-
-
-
-
-
-
-
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

